KPV

Derived from the hormone alpha-MSH, this three-amino acid sequence has captured attention from researchers investigating inflammatory bowel disease and dermatological conditions. The peptide appears to retain the anti-inflammatory benefits of its parent hormone while avoiding the skin pigmentation effects that make full alpha-MSH problematic for therapeutic use. Most research activity centers around gastrointestinal inflammation and wound healing applications.

KPV works by interfering with the cellular machinery that produces inflammatory signals, particularly targeting the pathways that generate cytokines like TNF-alpha and interleukin-1. Think of it as a molecular switch that turns down inflammation without completely shutting off the immune system's ability to respond to genuine threats. The peptide appears to accomplish this through interactions with melanocortin receptors, but in a way that specifically affects inflammation rather than pigmentation.